Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]
Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $85.00 target price on the stock. IRON has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $43.00 price […]
Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $85.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 148.97% from the company’s current price. Several […]
Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $85.00 price target on the stock. Several other research analysts have also weighed in on IRON. Stifel Nicolaus upped their price target on Disc Medicine from […]
Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price […]